Umecrine Cognition Study Misses PBC Efficacy Endpoints
Golexanolone showed no statistically significant benefit versus placebo on the prespecified PBC-40 cognition endpoint or supportive fatigue analysis in Part B of the Phase 1b/2a PBC study. Safety was acceptable; next steps for the indication are under review.